Latest Breaking News On - Loa update - Page 1 : vimarsana.com

Mauna Loa News | Latest News

Latest news on Mauna Loa, a large shield volcano on the island of Hawaii. It is the largest volcano in the world by mass

गोव्यात काँग्रेसचे 8 आमदार भाजपमध्ये, देवाला विचारून घेतला निर्णय : कामत | 8 Congress MLAs join BJP in Goa, decision taken by asking God: Kamat

काँग्रेसचे नेते राहुल गांधी यांची भारत जोडो यात्रा सुरू असतानाच गोव्यात पक्षात फूट पडली. काँग्रेसचे ११ पैकी ८ आमदार बुधवारी भाजपमध्ये विलीन झाले. त्यात माजी मुख्यमंत्री दिगंबर कामत यांचाही समावेश आहे. गोव्याचे मुख्यमंत्री प्रमोद सावंत आणि भाजपचे प्रदेशाध्यक्ष सदानंदशेठ तानवडे यांच्या उपस्थितीत काँग्रेसच्या आमदारांनी भाजपचे सदस्यत्व स्वीकारले. पक्षातील फूट म्हणजे ‘ऑपरेशन कीचड’ असल्याची टिप्पणी काँग... | Goa Congreess MLA joint Bjp | 8 Congress MLAs join BJP in Goa, decision taken by asking God: Kamat गोव्यात काँग्रेसचे 8 आमदार भाजपमध्ये, देवाला विचारून घेतला निर्णय : कामत

Aimmune's AR201 PTSR increase as Phase II trial is completed

Imara's IMR-687 for sickle cell disease, beta thalassaemia sees surge

Amgen's bemarituzumab LoA in GEJ and gastric cancers jumps

BioLineRx's approval likelihood for motixafortide bolstered by 9 points

Roche's Gazyvaro approval prospects in HCL increased by 10 points

By Reynald Castaneda 12 May 2021 (Last Updated May 12th, 2021 13:38) Roche’s Gazyvaro (obinutuzumab) has its Likelihood of Approval (LoA) jumping by 10 points in hairy cell leukaemia (HCL) on the heels of the investigator-led Phase I/II basket trial’s recruitment completion update on 29 April. This LoA change is in combination with Phase I/II data showing obinutuzumab, plus Gilead Sciences’ entospletinib, is effective and well-tolerated in refractory or recurrent CLL. Credits: Medtech THAI STUDIO LAB 249/Shutterstock.com. Share Article Roche’s Gazyvaro (obinutuzumab) has its Likelihood of Approval (LoA) jumping by 10 points in hairy cell leukaemia (HCL) on the heels of the investigator-led Phase I/II basket trial’s recruitment completion update on 29 April. This LoA change is in combination with Phase I/II data showing obinutuzumab, plus Gilead Sciences’ entospletinib, is effective and well-tolerated in refractory or recurrent chronic lymphocytic leukaemia (CLL), as presented in November 2019.